IGF Oncology

IGF Oncology, LLC, is a Delaware limited liability company based in Minnesota. It is a clinical stage pharmaceutical company developing targeted cancer drugs.
Lead Drug IGF-MTX
• Insulin-like growth factor variant protein attached to the chemotherapy drug methotrexate.
• Targets a receptor protein, IGF-1R, overexpressed on cancer, so it is a targeted chemotherapy that selectively targets and kills cancer cells and has less effect on healthy cells.
• Approximately 13 times more effective than methotrexate in mouse model of solid tumor cancers.
Phase 1 human clinical trial results:
• Effective at a surprisingly low dose, about 12 times lower dose than the minimum dose methotrexate is usually used at.
• ZERO decrease in blood cell counts, the most important side effect of standard chemotherapy.
Phase 2a clinical trial at Mayo Clinic in blood cancer.
• Phase 2a clinical trial at Mayo Clinic in deadly blood cancer myelodysplastic syndrome (MDS) opened in 2018. Two patients treated so far.
• Drug effective in both patients, at the lowest dose we will use in this trial. The two patients had a life expectancy of 3-6 months when they started our drug.
• IGF-MTX kills MDS cells in the laboratory and is synergistic with the two approved drugs. Also, the MDS cells have high IGF receptor levels.
• IGF-MTX is well suited for this disease because the patients cannot tolerate any decrease in blood cells, and unlike all other cancer chemotherapy, IGF-MTX does not cause any decrease in blood cells.
• Great business and medical opportunity because there are only 2 approved drugs for MDS and they don’t work very well.

Revenue:
5,000-10,000 new MDS patients per year in the U.S.
$250 million annual revenue in MDS in U.S. alone if IGF-MTX is approved.
Partnership in China:
Chinese Pharmaceutical company has pledged $10-20 million it will spend on clinical trials in China and will seek approval and market drug in China in exchange for 51% of profits in China. IGF Oncology will get 49% of profits in China.
Second drug: CPE-54
• For drug-resistant ovarian cancer
• Kills late stage ovarian cancer cells more effectively than early stage ovarian cancer.
• Extends life indefinitely in mouse model of ovarian cancer.
• Phase 1 human clinical trial in late stage ovarian cancer patients approved by FDA, to start in 2018
• Potential revenue at least $200 million annually in U.S. alone.
Intellectual Property
Strong IP protection. 5 issued U.S. patents cover IGF-MTX. Several other patents and applications.
Management:
Hugh McTavish, Ph.D., J.D., Founder and CEO. Dr. McTavish is a Ph.D. biochemist and patent attorney. He is the inventor or co-inventor of most of the company’s intellectual property. He is also a former cancer patient.
Dr. Arkadiusz Dudek, M.D., Ph.D. Chief Medical Officer. Dr. Dudek is a practicing oncologist and former professor at University of Minnesota and University of Illinois Medical Schools. He is Director of Phase 1 clinical trials at Regions Hospital, St. Paul, MN.